

Bond University
Research Repository



Fish oil supplementation and maintaining muscle mass in chronic disease: state of the evidence

Van der Meij, Barbara S; Mazurak, Vera

Published in:
Current Opinion in Clinical Nutrition and Metabolic Care

DOI:
[10.1097/MCO.0000000000000648](https://doi.org/10.1097/MCO.0000000000000648)

Licence:
Other

[Link to output in Bond University research repository.](#)

Recommended citation(APA):
Van der Meij, B. S., & Mazurak, V. (2020). Fish oil supplementation and maintaining muscle mass in chronic disease: state of the evidence. *Current Opinion in Clinical Nutrition and Metabolic Care*, 23(3), 164-173. Advance online publication. <https://doi.org/10.1097/MCO.0000000000000648>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

Current Opinion in Clinical Nutrition and Metabolism

Word count : 2523

Title of Review Article:

Fish Oil Supplementation and Maintaining Muscle Mass in Chronic Disease: State of the Evidence

Authors:

BS van der Meij^{1,2,3} and VC Mazurak⁴

Authors Affiliations:

¹ Bond University Nutrition and Dietetics Research Group, Faculty of Health Sciences & Medicine, Gold Coast, Australia

² Nutrition and Dietetics, Mater Group, Brisbane, Australia

³ Mater Research Institute, University of Queensland, Brisbane, Australia

⁴ Faculty of Agricultural Life and Environmental Sciences, University of Alberta, Edmonton, Canada

Author of Correspondence:

Name: Vera C. Mazurak

Address: Division of Human Nutrition
4-002 Li Ka Shing Center for Research Innovation
University of Alberta
Edmonton, Alberta, Canada

Telephone: 780-492-8048

Email: vmazurak@ualberta.ca

Abstract (196 words)

Purpose of Review: Providing EPA and DHA, in the form of fish oils, to benefit muscle is an emerging area of interest. The aim of this work was to evaluate the current literature that has assessed muscle mass as an outcome during a fish oil intervention in any chronic disease.

Recent Findings: The vast majority of studies published in the last 3 years (12 out of 15) have been conducted in the oncological setting, in patients undergoing treatment for cancers of the gastrointestinal tract, breast, head and neck, lung, cervix and hematological cancers. Three studies were conducted in patients with COPD. Fish oil was provided as part of a nutrient mixtures in 12 studies and as capsules in 3 studies.

Summary: Overall the evidence for an effect of fish oil supplementation on muscle mass in cancer patients undergoing treatment and in COPD remains unequivocal and reveals nothing new in the area of fish oil supplementation in the cancer setting which continues to provide mixed evidence on the efficacy of fish oil on muscle mass and function. This review highlights challenges in comparing and interpreting current studies aimed at testing fish oil supplementation for muscle health.

Key Words:

Skeletal muscle, EPA, DHA, clinical trials

Abbreviations

RCT	Randomised Controlled Trial
PUFA	PolyUnsaturated Fatty Acids
ONS	Oral Nutritional Supplement
RA	Rheumatoid Arthritis
GI	Gastrointestinal
DXA	Dual x-ray Absorptiometry
EPA	eicosapentaenoic acid
DHA	docosahexaenoic acid
COPD	Chronic Obstructive Pulmonary Disease
BIA	Bio-Impedance Analysis

Introduction

Chronic disease generally occurs in older individuals and exacerbates the normal physiology of aging which includes muscle loss. Chronic disease is generally associated with some degree of inflammation and altered hormone regulation impacting muscle health (1). Low muscle mass is a feature common to many chronic diseases, and often exists even at the time of diagnosis, with additional losses anticipated during the trajectory of chronic disease evoked by the disease process itself or the medications prescribed for managing the condition (2, 3). Sedentary lifestyles and poor diets may also contribute to the development of chronic disease and have a negative impact on muscle health.

Sarcopenia, or muscle mass below a specific threshold that is associated with disability, has received attention in recent years due to its association with poor outcomes in nearly all chronic diseases in which it has been evaluated. A more recent poor prognostic factor of low muscle attenuation (low muscle radiodensity) has been revealed by the opportunistic application of CT imaging and is associated with aberrant fat infiltration into muscle (4, 5). There have been several recent reviews on the association of body composition features with poor outcomes in aging (6), cancer (3), and chronic liver disease (7, 8). However, less is known about how to potentially modify these poor prognostic features with nutritional interventions.

Dietary n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), have well described immune-modulating effects, and have been studied with respect to modification of the burden of chronic disease. EPA and DHA are nutrients found in fatty fish and their oils, and can be encapsulated or provided as a component of oral nutritional supplements. This review evaluates recent evidence (published in the past three years) to determine whether provision of EPA and DHA, in the form of fish oil, is associated with improved muscle mass and/or function in chronic diseases.

Rationale for Study of EPA and DHA in Muscle Health

A handful of elegant studies have yielded positive results with respect to an attenuation of aging associated muscle loss when EPA and DHA are provided to older individuals. During healthy aging, n-3 PUFA supplementation improves muscle protein synthesis, strength and function as well as muscle mass (9, 10) in the absence of changes in inflammation. Pathways that have been explored include insulin stimulated pathways and mitochondrial function, both of which are enhanced in older humans supplemented with n-3 PUFA (11, 12). In conditions of insulin resistance, also common to many chronic diseases, n-3 PUFA improve insulin sensitivity even in the absence of gains in muscle mass (12-14). Nearly two decades of research in the cancer setting has additionally provided mixed evidence on the benefit of providing fish oil for maintenance of muscle mass (15, 16).

Status of n-3 fatty acids and Low muscle mass are generally independently evaluated in chronic diseases

Poor status of n-3 PUFA has been reported in many chronic diseases where low muscle mass has been reported separately including Rheumatoid Arthritis (RA) (17), Chronic Obstructive Pulmonary Disease (COPD) (18-20), liver disease (Non Alcoholic Fatty Liver Disease and cirrhosis) (21, 22); cancer (23-25); diabetes (17, 26, 27), Chronic Kidney Disease (28), Heart Disease (29) and Alzheimer's disease (30-32). The two features of poor n-3 PUFA status and low muscle mass may be related events rather than isolated events (23). Studies that have evaluated nutritional interventions with fish oils typically evaluate disease markers, and/or inflammation. These outcomes are rarely evaluated in tandem with body composition. Further, to our knowledge, no study has directly investigated mechanisms of action of EPA and DHA to evaluate a change in muscle protein synthesis and protein breakdown in a chronic disease condition.

Update on n-3 PUFA interventions in Chronic Disease where Muscle is Assessed as an outcome

A broad search of the literature over the past three years revealed 15 studies that have applied an n-3 PUFA intervention and measured muscle or lean body mass as an outcome. Twelve of these studies were conducted in the oncology setting; the additional three studies were conducted in COPD. Therefore, a major gap in the literature are studies that assess muscle mass during an n-3 PUFA intervention in other chronic diseases associated with muscle loss, such as RA and liver disease.

Cancer

The majority of people diagnosed with cancer experience muscle loss during their disease trajectory. The importance of maintaining muscle mass in the oncology setting is well established (33, 34). Loss of muscle is accelerated in cancer due to tumor metabolism, delivery of toxic drugs and limited food intake. N-3 PUFA supplementation studies in patients undergoing active treatment published since the early 2000s documented benefits on tumor response, prevention of toxicities, inflammation and maintenance of muscle mass (15, 35, 36). Studies published in the past three years were conducted in patients gastrointestinal (4 studies), head and neck (3 studies), breast cancer (2 studies), lung (1 study), cervical (1 study) and hematological cancer (1 study; Table 1).

Gastrointestinal Cancers

Four studies were conducted in patients with gastrointestinal cancer, including gastric, pancreatic and colorectal cancer, undergoing neoadjuvant chemotherapy or surgery. Sample sizes ranged from 20-34 per group. None of the studies evaluated outcome measures separately for men and women. The age of the participants varied from 30 y to 90 y to include a broad range of expected

muscle mass. All nutritional interventions for GI cancers used mixtures containing EPA and DHA, with three studies applying an ONS, and one study using capsules to provide fish oil alone or in combination with vitamin D. Two of three studies using an ONS provided additional calories and protein compared to the “control” intervention (37-39), one study (40) matched the control group with an equivalent amount of calories and protein. Compliance to the supplement was either not reported or reported to be a challenge impeding interpretation of the results. Results were varied with no effect, weight gain and increase in muscle mass being reported following the intervention. In the single study that used capsules containing vitamin D and fish oil, four groups were evaluated: 1) placebo, 2) fish oil, 3) vitamin D and 4) fish oil plus vitamin D. For each group, placebo capsules were provided. This study reported an increase in fat free mass in the fish oil groups (with and without vitamin D) (41).

Head and Neck Cancer

All of the studies conducted in the head and neck population used a nutrient mixture in the form of ONS. Two of the studies were comparable with respect to the supplement provided as well as duration of the intervention (42, 43). Neither of these studies showed an effect of supplementation on any of the assessed parameters. The third study provided ONS containing EPA and DHA during 6 weeks of treatment (44). Using a similar dose as other studies (2 g EPA/d), this group showed a stabilization of body weight and lean body mass, whereas the control group lost both weight and lean body mass. The intervention group also experienced an improvement in fatigue and measures of inflammation. Results of these studies are reported as a change over time in the intervention group rather than between groups as intended. Poor compliance to ONS is expected in this group experiencing a high symptom burden, although this was not assessed in the studies reviewed.

Breast Cancer

Two randomised controlled trials (RCTs) evaluated EPA and DHA in breast cancer patients; one during a chemotherapy regimen (45) and one in treatment naive patients awaiting surgery (46), therefore the intervention duration was different between the studies. Both studies provided EPA and DHA in the form of capsules. No changes in fat free mass neither during the intervention nor between the groups was observed (45, 46).

Other cancers

The other cancer categories included malnourished cervical cancer patients (47), weight losing NSCLC patients (48), and patients with mixed types of hematological malignancies (49). In cervical cancer patients, no absolute difference between intervention groups was reported for lean body mass (47). Laviano et al. reported no difference in lean body mass between a group of NSCLC patients receiving a nutrient mixture containing EPA and DHA compared to a placebo. Chagas et al. reported greater mid arm muscle

circumference in hematological cancer patients prescribed fish oil capsules during 9 weeks of treatment. Reporting results as a function of compliance resulted in small sample sizes in each subgroup.

Chronic Obstructive Pulmonary Disease (COPD)

Three studies in the past 3 years evaluated an n-3 PUFA supplementation in COPD patients, albeit having very different study designs (50-52). Calder et al. provided two containers of an ONS containing 1200 mg DHA and 800 mg EPA per day. Plasma n-3/n-6 ratios showed 79% of the intervention group achieved compliance. Improvements in symptoms (fatigue, dyspnea, walking distance) were observed, however, there were no changes in inflammation markers, activity scores, appetite or muscle mass after a 12 week intervention (50).

A second study in COPD patients in an open label study design provided a fish oil containing ONS during hospitalization for an acute phase of disease activity. On average, patients were hospitalized for one week and remained on the supplement until discharge. Longer hospital stay (receiving more supplements over time) was positively correlated with lean body mass (51).

A third study was conducted in COPD patients with low muscle mass who were undergoing rehabilitation on an outpatient basis. The nutritional intervention was comprised of a mixture of EPA and DHA, with leucine and vitamin D provided for 4 months concurrent with an intense exercise program. The control group received a placebo drink, therefore groups were not matched for calories or protein. Importantly, however, this study assessed the plasma levels of EPA and DHA at baseline and also compared these values to healthy controls. Both groups receiving n-3 PUFA experienced improved skeletal muscle mass, quadriceps muscle strength and cycle endurance time, inspiratory muscle strength only improved in the supplement group. Therefore there was an effect on function without a change in muscle mass (52).

Summary of Recent Literature

The studies applying fish oil interventions to evaluate effects on muscle health are currently almost exclusively been conducted in the oncology setting. Collectively, the literature over the past 3 years conducted in cancer and COPD does not strengthen the evidence base to support fish oil intervention to maintain muscle mass and there were no two studies that were similar in intervention, disease state, and outcomes. In general, studies suffer from limited, and often unjustified sample sizes where subgroup effects (such as age, sex or tumor site) are not able to be explored. A limitation in the ability to interpret studies also lies in the reporting of a change within the supplemented group over time, whereas in a RCT design, the difference between the two groups should be evaluated. Studies

reporting change over time in the intervention group when a difference between groups was not observed causes a bias to overestimate effects. Study design considerations for future studies are highlighted in Figure 1.

The prescribed dose of n-3 PUFA is generally reported, but not the actual dose taken. Only 4 out of 15 studies reported a biological measure of compliance. The prevailing literature suggests that an effective dose of fish oil is approximately 2 g per day (15, 16, 53-55), but whether that is total n-3, EPA and/or DHA remains to be determined. Dose justification is not referenced in the majority of reviewed studies and some used a lower dose (e.g. 1 g EPA per day). Poor compliance to fish oil containing supplements has been known for >15 years, therefore not having a measure of compliance is problematic. When there is no biological measure of compliance, one cannot relate the outcome measure to a specific amount of EPA or DHA achieved during the supplemental period. This information is required to enable an estimation of the required amount of EPA and DHA required to see a benefit should one exist. This remains a major gap in the area of nutritional supplementation studies. Importantly, EPA and DHA are dietary essential nutrients and patients with cancer (56) and COPD (52) have levels of EPA and DHA that are lower than comparable controls in the healthy population, which could be a result of the disease process, altered metabolism, poor diets, or a difference in essential fatty acid requirements. With the absence of plasma measures of n-3 fatty acids, it is challenging to know whether EPA and DHA are “supplemented” or restored nor do we know the level required to see a biological impact on the outcome of interest.

Studies showed no attention to or mention of age, sex or co-morbidities. Having specific diagnoses that affect muscle is often an exclusion criteria for entry into RCT that evaluate muscle mass. However, apart from diagnosed diseases per se, cancer patients are known to have one or more comorbidities at presentation (57). This contributes to poor muscle condition (58) in addition to the medications prescribed to manage those conditions. None of the studies evaluated men and women separately. It is known that there is considerable sexual dimorphism in muscle responses and responses to interventions (59-61). In order to better understand who is most likely to benefit from interventions, the analysis needs to account for this. Food intake and EPA and DHA intake from other sources is rarely assessed, even though the baseline diet is a key consideration in whether or not a person may respond to supplemental EPA and DHA. Further, adequate energy and muscle building nutrients are required to reach an anabolic response.

Perhaps even more important than muscle mass, is muscle function. Two studies that included an evaluation of muscle function showed a benefit. No study evaluated mechanisms although some associations of muscle mass with markers of inflammation in the blood were attempted recognizing inflammation to be driving muscle loss in chronic disease. The majority of studies applied bio-impedance analysis (BIA) to measure their primary outcome of muscle mass or lean body mass, however, BIA assesses fat free mass (including bone, organs and muscle) and not specifically skeletal muscle mass.

Conclusion

The set of literature published in the past 3 years does not strengthen the base of mixed evidence that has built over the past decades investigating muscle loss that occurs in chronic disease. The literature continues to provide mixed evidence on the efficacy of EPA and DHA for muscle mass and only reports on studies conducted in COPD and cancer. ESPEN guidelines for oncology patients recommend the use of fish oil supplements during cancer treatment and in patients expected to experience muscle loss however, this recommendation is based on weak evidence. The most recent systematic review effects of fish oils in the cancer setting concluded that provision of fish oils concurrent with chemotherapy is beneficial to body composition, an effect only seen in well-designed studies (15, 53). As has been previously reported, the safety and lack of harm from of n-3 PUFA supplementation was evident. However, to obtain more evidence base, RCTs in large, homogenous groups are needed. This can be achieved by forging collaborations between research groups and clinicians and to conduct multi-centre trials to enhance the evidence required to move from weak evidence regarding nutritional interventions in chronic diseases.

Key points

- Few studies outside of oncology have applied fish oil supplementation in tandem with measures of muscle mass
- Due to study design limitations, the evidence base on the benefit of fish oil on muscle mass is not enhanced by recently published research
- Clinical trials applying fish oil supplementation currently do not account for expected differences in age, sex, dietary intakes and co-morbidities as contributors to muscle mass
- Reporting on and measuring compliance remains an obstacle to building an evidence base in the area of fish oil supplementation in chronic disease

Figure Legends

FIGURE 1: A checklist of considerations for future studies designed to assess a nutritional intervention on muscle mass in chronic disease.

Acknowledgements

We would like to thank Dr. Liz Isenring and Dr. Lisa Martin for their critical review of the manuscript.

Financial Support

Faculty of Health Sciences and Medicine, University of Bond, Visiting Academic Award

Conflicts of Interest

The authors have no conflict of interests to declare.

References and Recommended Readings

References of particular interest:

25 (Pratt et al, 2002)

**References of special interest:*

33 (Fearon et al, 2013), 58 (Xiao et al, 2018), 56 (Murphy et al, 2012)

***References of outstanding interest:*

3 (Shachar et al, 2016), 5 (Bhullar et al, 2020), 15 (de van der Schueren et al, 2018)

1. Dupont J, Dedeyne L, Dalle S, Koppo K, Gielen E. The role of omega-3 in the prevention and treatment of sarcopenia. *Aging clinical and experimental research*. 2019;31(6):825-36. Epub 2019/02/21.
2. Johnson Stoklossa CA, Sharma AM, Forhan M, Siervo M, Padwal RS, Prado CM. Prevalence of Sarcopenic Obesity in Adults with Class II/III Obesity Using Different Diagnostic Criteria. *Journal of nutrition and metabolism*. 2017;2017:7307618. Epub 2017/04/20.
3. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. *European journal of cancer (Oxford, England : 1990)*. 2016;57:58-67. Epub 2016/02/18.
4. Ewaschuk JB, Almasud A, Mazurak VC. Role of n-3 fatty acids in muscle loss and myosteatosis. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme*. 2014;39(6):654-62. Epub 2014/05/30.
5. Bhullar AS, Anoveros-Barrera A, Dunichand-Hoedl A, Martins K, Bigam D, G. Khadaroo R, et al. Lipid is heterogeneously distributed in muscle and associates with low radiodensity in cancer patients. *Journal of cachexia, sarcopenia and muscle*. 2020;in press.
6. Liu P, Hao Q, Hai S, Wang H, Cao L, Dong B. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: A systematic review and meta-analysis. *Maturitas*. 2017;103:16-22. Epub 2017/08/06.
7. Tovo CV, Fernandes SA, Buss C, de Mattos AA. Sarcopenia and non-alcoholic fatty liver disease: Is there a relationship? A systematic review. *World journal of hepatology*. 2017;9(6):326-32. Epub 2017/03/16.
8. Ooi PH, Hager A, Mazurak VC, Dajani K, Bhargava R, Gilmour SM, et al. Sarcopenia in Chronic Liver Disease: Impact on Outcomes. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2019;25(9):1422-38. Epub 2019/06/27.
9. Logan SL, Spriet LL. Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females. *PloS one*. 2015;10(12):e0144828. Epub 2015/12/19.
10. Smith GI, Julliard S, Reeds DN, Sinacore DR, Klein S, Mittendorfer B. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. *The American journal of clinical nutrition*. 2015;102(1):115-22. Epub 2015/05/23.
11. Lalia AZ, Johnson ML, Jensen MD, Hames KC, Port JD, Lanza IR. Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans. *Diabetes care*. 2015;38(7):1228-37. Epub 2015/04/09.

12. Gao H, Geng T, Huang T, Zhao Q. Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis. *Lipids in health and disease*. 2017;16(1):131. Epub 2017/07/05.
13. Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, Shipp LR, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. *Diabetes*. 2013;62(5):1709-17. Epub 2013/01/19.
14. Buoite Stella A, Gortan Cappellari G, Barazzoni R, Zanetti M. Update on the Impact of Omega 3 Fatty Acids on Inflammation, Insulin Resistance and Sarcopenia: A Review. *International journal of molecular sciences*. 2018;19(1). Epub 2018/01/13.
15. de van der Schueren MAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2018;29(5):1141-53. Epub 2018/05/23.
16. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. *Nutrition*. 1996;12(1 Suppl):S27-30. Epub 1996/01/01.
17. Petersson S, Philippou E, Rodomar C, Nikiphorou E. The Mediterranean diet, fish oil supplements and Rheumatoid arthritis outcomes: evidence from clinical trials. *Autoimmunity reviews*. 2018;17(11):1105-14. Epub 2018/09/15.
18. Rozenberg D, Martelli V, Vieira L, Orchanian-Cheff A, Keshwani N, Singer LG, et al. Utilization of non-invasive imaging tools for assessment of peripheral skeletal muscle size and composition in chronic lung disease: A systematic review. *Respiratory medicine*. 2017;131:125-34. Epub 2017/09/28.
19. Pizzini A, Filipiak W, Wille J, Ager C, Wiesenhofer H, Kubinec R, et al. Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease. *Journal of breath research*. 2018;12(3):036002. Epub 2018/01/04.
20. Fulton AS, Hill AM, Williams MT, Howe PR, Coates AM. Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review. *Nutrition reviews*. 2015;73(9):612-23. Epub 2015/07/18.
21. Yang J, Fernandez-Galilea M, Martinez-Fernandez L, Gonzalez-Muniesa P, Perez-Chavez A, Martinez JA, et al. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. *Nutrients*. 2019;11(4). Epub 2019/04/21.
22. Scorletti E, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. *Molecular aspects of medicine*. 2018;64:135-46. Epub 2018/03/17.
23. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. *The Journal of nutrition*. 2010;140(9):1602-6. Epub 2010/07/16.
24. Zuijdgheest-van Leeuwen SD, van der Heijden MS, Rietveld T, van den Berg JW, Tilanus HW, Burgers JA, et al. Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. *Clinical nutrition*. 2002;21(3):225-30. Epub 2002/07/20.
25. Pratt VC, Watanabe S, Bruera E, Mackey J, Clandinin MT, Baracos VE, et al. Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. *British journal of cancer*. 2002;87(12):1370-8. Epub 2002/11/28.
26. Mozaffari H, Daneshzad E, Larijani B, Bellissimo N, Azadbakht L. Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: a systematic review and meta-analysis of observational studies. *European journal of nutrition*. 2019. Epub 2019/01/27.

27. Julibert A, Bibiloni MDM, Tur JA. Dietary fat intake and metabolic syndrome in adults: A systematic review. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2019;29(9):887-905. Epub 2019/08/05.
28. Saglimbene VM, Wong G, van Zwieten A, Palmer SC, Ruospo M, Natale P, et al. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. *Clinical nutrition*. 2019. Epub 2019/03/25.
29. Pizzini A, Lunger L, Sonnweber T, Weiss G, Tancevski I. The Role of Omega-3 Fatty Acids in the Setting of Coronary Artery Disease and COPD: A Review. *Nutrients*. 2018;10(12). Epub 2018/12/06.
30. Devassy JG, Leng S, Gabbs M, Monirujjaman M, Aukema HM. Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease. *Advances in nutrition (Bethesda, Md)*. 2016;7(5):905-16. Epub 2016/09/17.
31. Solfrizzi V, Custodero C, Lozupone M, Imbimbo BP, Valiani V, Agosti P, et al. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review. *Journal of Alzheimer's disease : JAD*. 2017;59(3):815-49. Epub 2017/07/13.
32. Fraga VG, Carvalho MDG, Caramelli P, de Sousa LP, Gomes KB. Resolution of inflammation, n-3 fatty acid supplementation and Alzheimer disease: A narrative review. *Journal of neuroimmunology*. 2017;310:111-9. Epub 2017/08/06.
33. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. *Nature reviews Clinical oncology*. 2013;10(2):90-9. Epub 2012/12/05.
34. Baracos VE, Mazurak VC, Bhullar AS. Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. *Annals of palliative medicine*. 2019;8(1):3-12. Epub 2019/01/29.
35. Gu Z, Shan K, Chen H, Chen YQ. n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention. *Current pharmacology reports*. 2015;1(5):283-94. Epub 2015/10/13.
36. Morland SL, Martins KJB, Mazurak VC. n-3 polyunsaturated fatty acid supplementation during cancer chemotherapy. *Journal of Nutrition & Intermediary Metabolism*. 2016;5:107-16.
37. Akita H, Takahashi H, Asukai K, Tomokuni A, Wada H, Marukawa S, et al. The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study. *Clinical nutrition ESPEN*. 2019;33:148-53. Epub 2019/08/28.
38. Aoyama T, Yoshikawa T, Ida S, Cho H, Sakamaki K, Ito Y, et al. Effects of perioperative Eicosapentaenoic acid-enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer. *Journal of Cancer*. 2019;10(5):1070-6. Epub 2019/03/12.
39. Ida S, Hiki N, Cho H, Sakamaki K, Ito S, Fujitani K, et al. Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer. *The British journal of surgery*. 2017;104(4):377-83. Epub 2017/01/11.
40. Feijo PM, Rodrigues VD, Viana MS, Dos Santos MP, Abdelhay E, Viola JP, et al. Effects of omega-3 supplementation on the nutritional status, immune, and inflammatory profiles of gastric cancer patients: A randomized controlled trial. *Nutrition*. 2019;61:125-31. Epub 2019/02/03.
41. Haidari F, Abiri B, Irvani M, Razavi SM, Sarbakhsh P, Ahmadi-Angali K, et al. Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial. *Trials*. 2019;20(1):682. Epub 2019/12/10.
42. Hanai N, Terada H, Hirakawa H, Suzuki H, Nishikawa D, Beppu S, et al. Prospective randomized investigation implementing immunonutritional therapy using a nutritional supplement with a high blend ratio of omega-3 fatty acids during the perioperative period for head and neck carcinomas. *Japanese journal of clinical oncology*. 2018;48(4):356-61. Epub 2018/02/09.

43. Jantharapattana K, Orapipatpong O. Efficacy of EPA-enriched supplement compared with standard formula on body weight changes in malnourished patients with head and neck cancer undergone surgery: a randomized study. *Head & neck*. 2019. Epub 2019/10/28.
44. Solis-Martinez O, Plasa-Carvalho V, Phillips-Sixtos G, Trujillo-Cabrera Y, Hernandez-Cuellar A, Queipo-Garcia GE, et al. Effect of Eicosapentaenoic Acid on Body Composition and Inflammation Markers in Patients with Head and Neck Squamous Cell Cancer from a Public Hospital in Mexico. *Nutrition and cancer*. 2018;70(4):663-70. Epub 2018/04/27.
45. de la Rosa Oliva F, Meneses Garcia A, Ruiz Calzada H, Astudillo de la Vega H, Bargallo Rocha E, Lara-Medina F, et al. Effects of omega-3 fatty acids supplementation on neoadjuvant chemotherapy-induced toxicity in patients with locally advanced breast cancer: a randomized, controlled, double-blinded clinical trial. *Nutricion hospitalaria*. 2019;36(4):769-76. Epub 2019/06/14. Efecto de la suplementacion con acidos grasos omega -3 sobre la toxicidad secundaria a quimioterapia neoadyuvante en pacientes con cancer de mama localmente avanzado: ensayo clinico aleatorizado.
46. Paixao E, Oliveira ACM, Pizato N, Muniz-Junqueira MI, Magalhaes KG, Nakano EY, et al. The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naive breast cancer patients: a randomized double-blind controlled trial. *Nutrition journal*. 2017;16(1):71. Epub 2017/10/25.
47. Aredes MA, da Camara AO, de Paula NS, Fraga KYD, do Carmo M, Chaves GV. Efficacy of omega-3 supplementation on nutritional status, skeletal muscle, and chemoradiotherapy toxicity in cervical cancer patients: A randomized, triple-blind, clinical trial conducted in a middle-income country. *Nutrition*. 2019;67-68:110528. Epub 2019/08/25.
48. Laviano A, Calder PC, Schols A, Lonqvist F, Bech M, Muscaritoli M. Safety and Tolerability of Targeted Medical Nutrition for Cachexia in Non-Small-Cell Lung Cancer: A Randomized, Double-Blind, Controlled Pilot Trial. *Nutrition and cancer*. 2019:1-12. Epub 2019/07/11.
49. Chagas TR, Borges DS, de Oliveira PF, Mocellin MC, Barbosa AM, Camargo CQ, et al. Oral fish oil positively influences nutritional-inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on long-term survival: a randomised clinical trial. *Journal of human nutrition and dietetics : the official journal of the British Dietetic Association*. 2017;30(6):681-92. Epub 2017/04/05.
50. Calder PC, Laviano A, Lonqvist F, Muscaritoli M, Ohlander M, Schols A. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. *Journal of cachexia, sarcopenia and muscle*. 2018;9(1):28-40. Epub 2017/09/12.
51. Ogasawara T, Marui S, Miura E, Sugiura M, Matsuyama W, Aoshima Y, et al. Effect of eicosapentaenoic acid on prevention of lean body mass depletion in patients with exacerbation of chronic obstructive pulmonary disease: A prospective randomized controlled trial. *Clinical nutrition ESPEN*. 2018;28:67-73. Epub 2018/11/06.
52. van de Bool C, Rutten EPA, van Helvoort A, Franssen FME, Wouters EFM, Schols A. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. *Journal of cachexia, sarcopenia and muscle*. 2017;8(5):748-58. Epub 2017/06/14.
53. de Aguiar Pastore Silva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and/or radiotherapy: A systematic review. *Clinical nutrition*. 2015;34(3):359-66. Epub 2015/04/25.
54. Barber MD, Fearon KC, Tisdale MJ, McMillan DC, Ross JA. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. *Nutrition and cancer*. 2001;40(2):118-24. Epub 2002/04/19.
55. Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is

- mediated via suppression of interleukin-6. *Clinical science* (London, England : 1979). 1997;92(2):215-21. Epub 1997/02/01.
56. Murphy RA, Bureyko TF, Mourtzakis M, Chu QS, Clandinin MT, Reiman T, et al. Aberrations in plasma phospholipid fatty acids in lung cancer patients. *Lipids*. 2012;47(4):363-9. Epub 2011/12/14.
57. Renzi C, Kaushal A, Emery J, Hamilton W, Neal RD, Rachet B, et al. Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. *Nature reviews Clinical oncology*. 2019;16(12):746-61. Epub 2019/07/28.
58. Xiao J, Caan BJ, Weltzien E, Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al. Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. *Journal of cachexia, sarcopenia and muscle*. 2018;9(4):654-63. Epub 2018/04/21.
59. Anoveros-Barrera A, Bhullar AS, Stretch C, Esfandiari N, Dunichand-Hoedl AR, Martins KJB, et al. Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients. *Journal of cachexia, sarcopenia and muscle*. 2019;10(6):1356-77. Epub 2019/07/16.
60. Da Boit M, Sibson R, Sivasubramaniam S, Meakin JR, Greig CA, Aspden RM, et al. Sex differences in the effect of fish-oil supplementation on the adaptive response to resistance exercise training in older people: a randomized controlled trial. *The American journal of clinical nutrition*. 2017;105(1):151-8. Epub 2016/11/18.
61. Stephens NA, Gray C, MacDonald AJ, Tan BH, Gallagher IJ, Skipworth RJ, et al. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. *Clinical nutrition*. 2012;31(4):499-505. Epub 2012/02/03.

Figure 1. Study Design Checklist

Study Design Checklist

- Use an RCT design (preferably double blinded) and follow the PRISMA guidelines
- Use intention-to-treat analysis and report comparisons between groups rather than within groups
- Use an adequate sample size to ensure statistical power to compare on primary (and secondary) outcome(s)
- Report patients % weight loss, tumour type, tumor stage and inflammatory status at baseline
- Monitor and report patients dietary energy and protein intake at baseline and follow up during the study
- Assess plasma fatty acids at baseline and at the end of the intervention as a measure of compliance and to determine a dose response should one exist
- Report supplement composition in terms of content of EPA and DHA prescribed
- Adjust for sex and age in the analysis

Reference	Study design	Patient Population and Sample Size	Age ^a / Sex ^b Distribution	EPA/DHA (mg/d) Prescribed	Type	Control Group	Duration	Primary Outcome(s)
Gastrointestinal Cancers								
Feijo et al., 2019	RCT [open label]	Gastric cancer patients prior to surgery (n=66)	56% between 40-60y; 44% were >60y 44M:22F	EPA: 2200 DHA: 900	ONS	Standard ONS	30 days	Weight
Akita et al., 2019	RCT	Pancreatic cancer, receiving neoadjuvant chemoradiation therapy containing gemcitabine. (n=62)	67.8 + 10.7y 11M:20F	EPA: 2200 DHA: 900	ONS	Regular Diet	5 weeks	Pre/post ratios of skeletal muscle mass and psoas muscle area
Aoyama et al., 2019 & Ida et al., 2017	RCT [multi-center open label phase III]	Gastric cancer (Roux en Y) surgery (n=60)	30-80 y 43M:17F	EPA : 2200 DHA: 900	ONS	Regular Diet	pre-operatively for 6 days plus 21 days post surgery after oral intake resumed	Lean body mass
Haidari et al., 2019	RCT	Colorectal cancer, n=80 (3 intervention groups with fish oil ± vitamin D and a control group; n=20/group)	56.7 ± 12.5 y 46M:35F	EPA: 1100 DHA: 500	Capsules	Placebo	2 Capsules/d for 8 weeks (with and without vitamin D) versus placebo	Inflammatory markers and nutritional status
Head and Neck Cancer								
Hanai et al., 2018	RCT	Weight losing head and neck cancer (n=27)	45-77 y 16M:11F	EPA : 2200 DHA: 900	ONS	Standard ONS	14 days prior to surgery and 14 days after	Nutritional status

Jantharapattana et al., 2018	RCT	Head and neck cancer undergoing curative surgery (n=65)	55.2 ± 13.5 y 60M:12F	EPA: 2200 DHA: 900	ONS	Standard ONS	7 days prior to surgery and 14 days post operatively	Weight
Solis-Martinez et al., 2018	RCT	Head and Neck cancer (n=64)	59 ± 14y 35M:29F	EPA: 2000 DHA: ?	ONS	Iso-caloric Control	6 weeks	Body composition; inflammation
Breast Cancers								
De la Rosa et al., 2019	RCT	Breast Cancer Patients undergoing neoadjuvant therapy. (n=53)	28-72y Female	EPA: 1600 DHA: 800	Capsules	Placebo capsules	6 months	Body composition
Paixao et al., 2017	RCT	Treatment Naive Breast cancer patients (n=37)	40-60y Female	EPA: 940 DHA: 780	Capsules	Mineral oil capsules	30 days prior to surgery	Nutritional status
Other Cancers								
Aredes et al., 2019	RCT	Cervical cancer patients Treatment naive and those who had undergone curative treatment were included (n=40)	19-59 y Female	EPA: 2000 DHA: 500	Capsules	Placebo capsules		Skeletal muscle quantity and high-density skeletal muscle area
Laviano et al, 2019	RCT [Pilot]	Weight losing NSCLC patients undergoing first line chemotherapy (n=54)	64.4±7.7 y 38M: 17F	EPA: 1600 DHA: 2400	ONS	Standard Comparator	12 weeks	Safety and efficacy
Chagas et al., 2017	RCT	Mixed Hematological cancers undergoing chemotherapy (n=22)	43.8 + 23.3 y 12M:10F	EPA: 367 DHA: 243	Capsules	Placebo capsules	9 weeks	Nutritional status

Chronic Obstructive Pulmonary Disease								
Calder et al., 2018	RCT [multi-center]	COPD, pre-cachectic and cachectic (n=45)	69.2 ± 6.3 y 45M:55F	EPA: 1600 DHA: 2400	ONS	Standard Comparator	12 weeks	Lean body mass
Ogasawara et al., 2018	RCT [open label]	COPD; hospitalized and rehabilitation during hospitalization (n=45)	77.4 ±9.7 y 41M: 4F	EPA: 1100 DHA: 450	ONS		hospital stay (mean = 12.6 +/- 4.9 d, EPA group, 12.1+/-3.9 d, control group)	Lean body mass
van de Bool et al., 2017	RCT	COPD with low muscle mass undergoing outpatient rehabilitation (n=81)	43–80 y 51% males	EPA: 498-746 DHA: 237-356	ONS	Noncaloric liquid drink	4 months	Body weight, lean body mass, muscle strength

^aAge reported for the Intervention group

^bNumber of males and females in total reported

Table 2: Outcomes Assessed in Recent Literature

Reference	Biological Measure of Compliance?	Muscle Function?	Muscle Mass? (Method of assessment)	Food Intake?	Measure of Inflammation?
Feijo, Nutrition Journal 2019	X	X	X (BIA)	✓	✓
Akita, Clin Nutr ESPEN 2019	X	X	X (BIA and psoas by CT)	X	x
Aoyama, J Cancer 2019 & Ida, BJS 2017	X	X	X (BIA)	X	x
Haidari, J Diet Suppl 2019	X	X	X (BIA)	X	✓
Hanai, JJCO 2018	X	X	X (Not stated)	X	x
Jantharapattana, Head Neck 2018	X	X	X (BIA)	X	✓
Solis-Martinez, Nutr Ca 2018	X	X	X (BIA)	✓	x
De la Rosa et al, Nutricion Hospitalaria 2019	X	X	X (BIA)	X	✓
Paixao, Nutr J 2017	X	X	X (BIA)	✓	✓
Aredes, Nutrition 2019	X	X	X (unvalidated CT measure of psoas)	✓	x
Laviano, Nutr Cancer 2019	✓	X	✓ (Undescribed DXA and CT)	X	x
Chagas, J Hum Nutr	✓	X	✓	x	✓

Diet 2017			(anthropometrics)		
Calder, J Cachexia, Sarcopenia and Muscle 2018	✓	✓	✓ (DXA)	✓	✓
Ogasawara, Clin Nutr ESPEN 2018	X	X	X (BIA)	x	x
van de Bool, J Cach Sarc Muscle 2017	✓	✓	✓ (DXA)	x	x

X no ✓ yes